CalciMedica files prospectus supplement for up to $25 million stock sale

CalciMedica, Inc. reported in an 8-K dated September 30, 2026 that it had filed a prospectus supplement that day covering the potential sale of common stock. The supplement allows the company to offer and sell common stock with a combined offering price reaching $25,000,000 over time, under its at-the-market agreement with H.C. Wainwright & Co. dated August 11, 2023.¹

The filing falls under a broader shelf registration CalciMedica has on file with the SEC. That shelf registration, numbered 333-293972, was first submitted to the SEC on March 3, 2026, and became effective on March 11, 2026.¹

As part of the disclosure, CalciMedica included a legal opinion confirming the validity of the shares covered by the offering. That opinion, addressing the legality of the $25,000,000 in common stock issuable under the offering agreement and covered by the prospectus supplement, is attached as Exhibit 5.1.¹

The 8-K also lists supporting exhibits, including the Cooley LLP legal opinion and related consent, along with the standard cover page data file. The report is signed by A. Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, with a signing date of September 30, 2026. CalciMedica trades on The Nasdaq Capital Market under the ticker symbol CALC, and the company is based in La Jolla, California.